



(12) Translation of
European patent specification

(11) NO/EP 3447070 B1

NORWAY

(19) NO
(51) Int Cl.
C07K 16/10 (2006.01)
A61P 25/28 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2021.07.05
(80)	Date of The European Patent Office Publication of the Granted Patent	2021.02.24
(86)	European Application Nr.	18198309.9
(86)	European Filing Date	2013.10.01
(87)	The European Application's Publication Date	2019.02.27
(30)	Priority	2012.10.02, US, 201261708779 P 2012.12.28, US, 201261746792 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
(62)	Divided application	EP2904009, 2013.10.01
(73)	Proprietor	Geneuro SA, Chemin du Pré-Fleuri 3, 1228 Plan-Les-Ouates, Sveits
(72)	Inventor	PERRON, Hervé, 4 allée de la Guignonnière, 69290 Saint Genis les Ollières, Frankrike FIROUZI, Reza, -, deceased, Frankrike KÜRY, Patrick, Sperlingsweg 36, 40468 Dusseldorf, Tyskland FAUCARD, Raphaël, 348 route de Bonneville, 74130 Mont-Saxonnex, Frankrike MADEIRA, Alexandra, 3 route des Papeteries, 25320 Boussières, Frankrike JOANOU, Julie, 2 rue du pachyure, 42800 Rive de Gier, Frankrike
(74)	Agent or Attorney	BRYN AARFLOT AS, Stortingsgata 8, 0161 OSLO, Norge

(54)	Title	COMPOUNDS FOR TREATING THE REMYELINATION BLOCKADE IN DISEASES ASSOCIATED WITH THE EXPRESSION OF HERV-W ENVELOPE PROTEIN
(56)	References Cited:	WO-A1-2010/003977 WO-A2-2008/096271 KREMER DAVID ET AL: "The Complex World of Oligodendroglial Differentiation Inhibitors", ANNALS OF NEUROLOGY, vol. 69, no. 4, April 2011 (2011-04), pages 602-618, XP002716523, FRANÇOIS CURTIN ET AL: "GNbAC1, a Humanized Monoclonal Antibody Against the Envelope Protein of Multiple Sclerosis-Associated Endogenous Retrovirus: A First-in-Humans Randomized Clinical Study", CLINICAL THERAPEUTICS, vol. 34, no. 12, 1 December 2012 (2012-12-01), pages 2268-2278, XP055204753, ISSN: 0149-2918, DOI: 10.1016/j.clinthera.2012.11.006 SORMANI MARIA PIA ET AL: "Assessing Repair in Multiple Sclerosis: Outcomes for Phase II

Clinical Trials", NEUROTHERAPEUTICS, ELSEVIER INC, US, vol. 14, no. 4, 10 July 2017 (2017-07-10), pages 924-933, XP036543197, ISSN: 1933-7213, DOI: 10.1007/S13311-017-0558-3 [retrieved on 2017-07-10]

Alan J. Thompson ET AL: "Multiple sclerosis" In: "Outcomes in Neurological and Neurosurgical Disorders", 9 April 1998 (1998-04-09), Cambridge University Press, XP055711180, ISBN: 978-0-511-52694-7 pages 239-266, DOI: 10.1017/CBO9780511526947.015,

U.S. National Library of Medicine: "Safety Study of GNBAC1 in Multiple Sclerosis Patients NCT01639300", ClinicalTrials.gov , 12 July 2012 (2012-07-12), XP002786263, Retrieved from the Internet: URL:<https://clinicaltrials.gov/ct2/show/NCT01639300?id=NCT01639300&rank=1&load=cart> [retrieved on 2018-11-06]

LANG ALOIS B ET AL: "The therapeutic potential of monoclonal anti-human endogenous retrovirus W (HERV-W) envelope protein antibody in multiple sclerosis: Results from a new EAE-animal model", HUMAN ANTIBODIES, IOS PRESS, AMSTERDAM, NL, vol. 17, no. 1-2, 12 November 2008 (2008-11-12), page 21, XP009124418, ISSN: 1093-2607

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

PATENTKRAV

1. Anti-HERV-W Env-antistoff for anvendelse for behandling av
remyeliniseringsblokkering ved progressiv multippel sklerose assosiert
5 med ekspresjon av HERV-W-kappeprotein (ENV), hvor nevnte anti-
HERV-W Env-antistoff omfatter hvert av de komplementære- bestemte
regioner (CDRer) angitt i SEKV ID nr. 1, SEKV ID nr. 2, SEKV ID nr. 3
SEKV ID nr. 4, SEKV ID nr. 5 og SEKV ID nr. 6.
- 10 2. Anti-HERV-W Env-antistoff for anvendelse ifølge krav 1, hvor anti-
HERV-W Env-antistoffet er et scFv, et Fab-fragment, et kimært
antistoff, et konstruert eller et humanisert antistoff.
3. Anti-HERV-W Env-antistoff for anvendelse ifølge krav 1 eller 2, hvor
15 nevnte anti-HERV-W Env-antistoff er et IgG.
4. Anti-HERV-W Env-antistoff for anvendelse ifølge et hvilket som helst
av kravene 1 til 3, hvor anti-HERV-W Env-antistoffet er et IgG1.
- 20 5. Anti-HERV-W Env-antistoff for anvendelse ifølge et hvilket som helst
av kravene 1 til 3, hvor anti-HERV-W Env-antistoffet er et IgG4.
6. Anti-HERV-W Env-antistoff for anvendelse ifølge et hvilket som helst
av kravene 1 til 5, hvor den progressive multippel sklerose er sekundær
25 progressiv multippel sklerose (SPMS).
7. Anti-HERV-W Env-antistoff for anvendelse ifølge et hvilket som helst
av kravene 1 til 5, hvor den progressive multippel sklerose er Primary
Progressive Multiple Sclerosis (PPMS).